Ovid Therapeutics Inc. (OVID)

Ovid Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Net Income	-52.34	-54.17	122.83	-81.04	-60.46
Depreciation & Amortization	1.6	1.38	0.24	0.31	0.26
Share-Based Compensation	7.29	6.56	5.05	7.53	5.21
Other Operating Activities	-2.32	-9	-9.51	21.62	3.91
Operating Cash Flow	-45.78	-55.23	118.61	-51.58	-51.09
Capital Expenditures	-0.04	-1.22	-0.18	-0.13	-0.06
Change in Investments	-2.44	-86.46	-1.63	35.04	-29.8
Other Investing Activities	-0.1	-0.19	-0.01	-0.26	-0.19
Investing Cash Flow	-2.58	-87.88	-1.82	34.65	-30.04
Share Issuance / Repurchase	0.54	0.18	0.9	47.07	86.54
Debt Issued / Paid	30	0	0	0	0
Financing Cash Flow	30.54	0.18	0.9	47.07	86.54
Net Cash Flow	-17.83	-142.93	117.69	30.14	5.41
Free Cash Flow	-45.82	-56.45	118.43	-51.71	-51.15
Free Cash Flow Margin	-11698.19%	-3756.55%	56.83%	-409.85%	-
Free Cash Flow Per Share	-0.65	-0.80	1.75	-0.89	-1.30

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).